Like Crest, Potomac succeeds up to a point
Imfinzi hits on disease-free survival, but BCG won't be displaced.
Takeda says no to B7-H3
TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.
Revolution gets selective
The group’s latest update focused on new data with the KRAS G12C inhibitor elironrasib.
Ivonescimab takes on pancreatic cancer
Meanwhile, Exelixis and AstraZeneca continue to invest in pivotal trials of blockbuster follow-ons.
Amgen takes Imdelltra front line
Dellphi-312, testing Imdelltra plus PD-(L)1, will start mid-year.
Lantheus calls time on me-too Pluvicto
Final survival analysis draws a blank, and Lantheus throws in the towel.
The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
No holding back Claudin
New phase 1 entrants include Claudin18.2-targeting ADCs from Astra and Bolt.
Moderna returns to oncology
Three off-the-shelf mRNA therapies join intismeran autogene.
Vepdegestrant’s promise narrows
Arvinas and Pfizer abandon first-line atirmociclib combo plans only disclosed in January.
